Life sciences regulatory authorities in North America, Europe and Japan have been developing standards for drug and biologic registration submissions in electronic format for over ten years. The current version of the format—electronic Common Technical Document (eCTD)—has been the recommended format since 2005 and is on the way to becoming mandatory. At Documentation and Training Life Sciences, Antoinette Azevedo, president of e-SubmissionsSolutions.com, will open the pharmaceutical track with a presentation entitled Preparing Compliant eCTD Submissions. The session will provide attendees with an overview of best practices that will enable a sponsor to prepare a compliant eCTD for regulatory authority review. Here’s a sneak peek at why this topic is so important.

A California biotech submitted an eCTD to the US FDA in summer 2005. This company used commercial-off-the-shelf publishing software, experienced consultants, and in-house staff to compile this eCTD. This drug was the biotechs first candidate for commercialization. The biotech was partnered with big Pharma to assist with sales and marketing after the FDA authorized the drug for marketing. The biotech hired a sales force of nearly 200 in anticipation of FDA approval.

The FDA issued a refuse-to-file on this eCTD in fall 2005, due to problems with the PDF files and navigability of the content of the submission. The company’s market capitalization dropped 50% overnight. The company had to recompile the submission, by reworking the source files and rebuilding the XML backbone. The new version of the eCTD was resubmitted in early 2006. The FDA accepted the resubmission for review. 

However, in May 2006 the FDA issued an approvable letter, that meant the drug could be approved in the future if certain conditions were met (meaning yet another delay in being able to market the product, plus additional expense to conduct further clinical studies). In June, 2006, the big pharma company terminated the partnership with the biotech. In July 2006, the biotech laid off their sales force. In August, 2006, the biotech laid off 100 more employees. In September 2006, the biotech had a meeting with FDA to discuss what additional studies and analysis was needed. Finally, in January 2007, the biotech announced plans to resubmit its NDA by end of second quarter 2007.

The impact to the company’s stock price over three years is shown in the chart below.

This presentation will describe:

• Regulatory and business drivers behind the eCTD format
• Technical components of an eCTD
• Practical implications of collecting documents and data over the discovery, development, application review, and post-marketing lifecycle phases of a drug or biological product
• Global picture for adoption of the eCTD format
• Future direction for the eCTD format
• Role of electronic document management in the eCTD lifecycle
• Top 12 Issues FDA Has with eCTD and how to avoid them
• Preparing submission-ready source documents and data for submission in eCTD
• Whether to purchase an eCTD publishing system or to outsource.
• How to prepare for the technical challenges of eCTD

Don’t miss out on this extremely important session. Register today!